Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines
Self-replicating RNA vaccines delivered by viral replicon particles (VRPs) induce strong immunity, but repeated dosing on short intervals may be limited by vector responses. In patient samples and mice, VRP-srRNA vaccination generated VRP-neutralizing antibodies and T-cell responses to replicase. In mice, a third dose at two-week intervals minimally boosted transgene immunity, and prior VRP exposure reduced responses to a different-transgene VRP. Optimized schedules or heterologous prime-boost may sustain immunogenicity.
Authors
- Xingru Ma (ORCID: https://orcid.org/0000-0003-4964-4758)
- M. A. Morse
- Erika J. Crosby (ORCID: https://orcid.org/0000-0002-4872-6711)
- Amanda Summers
- Zachary C. Hartman (ORCID: https://orcid.org/0000-0001-6549-8207)
- Robert D. Marek (ORCID: https://orcid.org/0000-0001-5182-2811)
- Amy Hobeika (ORCID: https://orcid.org/0009-0007-5701-9027)
- Junping Wei
- Susannah Gammell
- Cong-Xiao Liu
- Tao Wang
- Gangjun Lei
- H. Kim Lyerly
Institutions
- Duke University (US)
Publication Details
- Journal
- npj Vaccines
- Published
- 2026-03-16
- DOI
- https://doi.org/10.1038/s41541-026-01423-x
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Susan G. Komen
- National Institutes of Health